101,239 Shares in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Bought by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. bought a new stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 101,239 shares of the company’s stock, valued at approximately $1,225,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after buying an additional 1,389 shares during the last quarter. Barclays PLC grew its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. Geode Capital Management LLC raised its holdings in Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the period. State Street Corp lifted its position in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Finally, FMR LLC purchased a new position in Gyre Therapeutics during the third quarter valued at $47,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Stock Down 1.5 %

NASDAQ GYRE opened at $11.43 on Tuesday. The stock’s 50-day moving average price is $11.44 and its 200-day moving average price is $12.37. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $22.00.

Insider Buying and Selling

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 30,054 shares of company stock valued at $342,277. 19.52% of the stock is owned by corporate insiders.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.